| __timestamp | CymaBay Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 1271353000 |
| Thursday, January 1, 2015 | 17026000 | 1620577000 |
| Friday, January 1, 2016 | 15941000 | 2052295000 |
| Sunday, January 1, 2017 | 18938000 | 2075142000 |
| Monday, January 1, 2018 | 58124000 | 2186100000 |
| Tuesday, January 1, 2019 | 83837000 | 3036600000 |
| Wednesday, January 1, 2020 | 35882000 | 2735000000 |
| Friday, January 1, 2021 | 64542000 | 2908100000 |
| Saturday, January 1, 2022 | 67995000 | 3592500000 |
| Sunday, January 1, 2023 | 80118000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
Regeneron has consistently led the charge, with R&D expenses growing by approximately 250% from 2014 to 2023. By 2023, their R&D spending reached a staggering $4.4 billion, underscoring their dedication to pioneering new treatments.
In contrast, CymaBay's R&D expenses, while significantly smaller, have shown a steady increase, rising by over 400% during the same period. This growth reflects their strategic focus on niche therapeutic areas.
These spending patterns highlight the diverse strategies within the biotech sector, where both large-scale and targeted investments play crucial roles in driving medical advancements.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Pharming Group N.V.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Veracyte, Inc.
Research and Development: Comparing Key Metrics for Regeneron Pharmaceuticals, Inc. and Perrigo Company plc
Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
R&D Spending Showdown: TG Therapeutics, Inc. vs CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs Geron Corporation